Aquestive Therapeutics Inc. (AQST)
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AQST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $434.88M
- EPS (TTM)
- -$0.65
- Dividend yield
- None
- 52-week range
- 2.93 – 6.74
- Day range
- 3.41 – 3.65
- Volume / Avg
- 3.35M / 2.41M
- Beta
- —
- Shares outstanding
- 125.69M
52-week range
AQST stock today
Shares of Aquestive Therapeutics (AQST) finished lower on Nov 20 at $3.46, a drop of 6.61% or $0.245 per share, versus the S&P 500's 3.70% decline. Shares are 48.6% below their 52-week high of $6.74, set on Dec 8, 2025 and 18.1% above the 52-week low of $2.93, near the bottom of the past year's range. AQST is down 46.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.5%.
Aquestive Therapeutics has posted a net loss over the last twelve months (EPS of -$0.65), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aquestive Therapeutics
Company profileAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel Barber
- Headquarters
- Warren, NJ
- Employees
- 147
- IPO year
- 2018
- Website
- aquestive.com
Financial highlights
Full financialsIn fiscal 2025, Aquestive Therapeutics generated $44.5 million in revenue, down 22.6% from fiscal 2024, its first annual decline since 2022. Aquestive Therapeutics reported a net loss of $83.8 million, compared with a loss of $44.1 million a year earlier. Gross margin was 58.3% (down from 69.0%) and operating margin -159.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M |
| Growth | -22.61% | +13.80% | +6.09% | -6.20% | +10.87% |
| Net income | $-83.78M | $-44.14M | $-7.87M | $-54.41M | $-70.54M |
| EPS (diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$9.33+169.65%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.13 vs $-0.10
- Surprise
- -30.00%
AQST news
All AQST news- Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Aquestive Therapeutics, Inc. Announces March 16, 2027 PDUFA Goal Date for Anaphylm NDA ResubmissionNasdaqAQST, BIO.B
- Aquestive (AQST) Q3 2026 Earnings Call TranscriptNasdaq
- Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Anaphylm UpdateNasdaq
- Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ETGlobeNewswire
- Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionNasdaqAQST, ET
- Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027GlobeNewswire
Aquestive Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs AQST |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs AQST |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs AQST |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs AQST |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs AQST |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs AQST |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs AQST |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs AQST |
Indexes, lists and sector
Aquestive Therapeutics stock FAQ
What is Aquestive Therapeutics's stock price today?
AQST last traded at $3.46 as of Nov 20, 4:00 PM EST, down 6.61% on the day. Prices are delayed at least 15 minutes.
Who is Aquestive Therapeutics's CEO?
Mr. Daniel Barber is the chief executive officer of Aquestive Therapeutics Inc., which has about 147 employees.
What is the AQST 52-week high?
The 52-week high for AQST is $6.74 and the 52-week low is $2.93. The stock is currently 48.6% below its high.